[Japon] Japan biotech startup pushes for mRNA shot suited for mass production

Auteur : Osamu Tsukimori, staff writer

Production : The Japan Times

Diffusion : site de The Japan Times

Date : 2 juin 2021

Wataru Akahata, CEO of VLP Therapeutics Japan LLC, thinks he can help provide a solution to the challenge of securing COVID-19 vaccines for billions of people — the development of a second-generation messenger RNA (mRNA) vaccine that requires only a fraction of the dosage of those currently available.

Source : Osamu Tsukimori, « Japan biotech startup pushes for mRNA shot suited for mass production », The Japan Times, 02/06/2021. URL : https://www.japantimes.co.jp/news/2021/06/02/national/vlp-replicon-covid-19-vaccine/ (consulté le 02/06/2021)

Photo « à la une » : Wataru Akahata, CEO of VLP Therapeutics Japan LLC. Akahata says that the startup’s animal experiments have confirmed its vaccine candidate’s efficacy against the more contagious coronavirus variants first identified in the U.K., South Africa and India. © VLP THERAPEUTICS JAPAN LLC.